Find information on thousands of medical conditions and prescription drugs.

Acute promyelocytic leukemia

Acute promyelocytic leukemia (APL; AML with t(15;17)(q22;q12) PML/RARα and variants; FAB subtype M3) is a subtype of acute myelogenous leukemia (AML), a cancer of the blood and bone marrow. more...

Home
Diseases
A
Aagenaes syndrome
Aarskog Ose Pande syndrome
Aarskog syndrome
Aase Smith syndrome
Aase syndrome
ABCD syndrome
Abdallat Davis Farrage...
Abdominal aortic aneurysm
Abdominal cystic...
Abdominal defects
Ablutophobia
Absence of Gluteal muscle
Acalvaria
Acanthocheilonemiasis
Acanthocytosis
Acarophobia
Acatalasemia
Accessory pancreas
Achalasia
Achard syndrome
Achard-Thiers syndrome
Acheiropodia
Achondrogenesis
Achondrogenesis type 1A
Achondrogenesis type 1B
Achondroplasia
Achondroplastic dwarfism
Achromatopsia
Acid maltase deficiency
Ackerman syndrome
Acne
Acne rosacea
Acoustic neuroma
Acquired ichthyosis
Acquired syphilis
Acrofacial dysostosis,...
Acromegaly
Acrophobia
Acrospiroma
Actinomycosis
Activated protein C...
Acute febrile...
Acute intermittent porphyria
Acute lymphoblastic leukemia
Acute lymphocytic leukemia
Acute mountain sickness
Acute myelocytic leukemia
Acute myelogenous leukemia
Acute necrotizing...
Acute promyelocytic leukemia
Acute renal failure
Acute respiratory...
Acute tubular necrosis
Adams Nance syndrome
Adams-Oliver syndrome
Addison's disease
Adducted thumb syndrome...
Adenoid cystic carcinoma
Adenoma
Adenomyosis
Adenosine deaminase...
Adenosine monophosphate...
Adie syndrome
Adrenal incidentaloma
Adrenal insufficiency
Adrenocortical carcinoma
Adrenogenital syndrome
Adrenoleukodystrophy
Aerophobia
Agoraphobia
Agrizoophobia
Agyrophobia
Aicardi syndrome
Aichmophobia
AIDS
AIDS Dementia Complex
Ainhum
Albinism
Albright's hereditary...
Albuminurophobia
Alcaptonuria
Alcohol fetopathy
Alcoholic hepatitis
Alcoholic liver cirrhosis
Alektorophobia
Alexander disease
Alien hand syndrome
Alkaptonuria
Alliumphobia
Alopecia
Alopecia areata
Alopecia totalis
Alopecia universalis
Alpers disease
Alpha 1-antitrypsin...
Alpha-mannosidosis
Alport syndrome
Alternating hemiplegia
Alzheimer's disease
Amaurosis
Amblyopia
Ambras syndrome
Amelogenesis imperfecta
Amenorrhea
American trypanosomiasis
Amoebiasis
Amyloidosis
Amyotrophic lateral...
Anaphylaxis
Androgen insensitivity...
Anemia
Anemia, Diamond-Blackfan
Anemia, Pernicious
Anemia, Sideroblastic
Anemophobia
Anencephaly
Aneurysm
Aneurysm
Aneurysm of sinus of...
Angelman syndrome
Anguillulosis
Aniridia
Anisakiasis
Ankylosing spondylitis
Ankylostomiasis
Annular pancreas
Anorchidism
Anorexia nervosa
Anosmia
Anotia
Anthophobia
Anthrax disease
Antiphospholipid syndrome
Antisocial personality...
Antithrombin deficiency,...
Anton's syndrome
Aortic aneurysm
Aortic coarctation
Aortic dissection
Aortic valve stenosis
Apert syndrome
Aphthous stomatitis
Apiphobia
Aplastic anemia
Appendicitis
Apraxia
Arachnoiditis
Argininosuccinate...
Argininosuccinic aciduria
Argyria
Arnold-Chiari malformation
Arrhythmogenic right...
Arteriovenous malformation
Arteritis
Arthritis
Arthritis, Juvenile
Arthrogryposis
Arthrogryposis multiplex...
Asbestosis
Ascariasis
Aseptic meningitis
Asherman's syndrome
Aspartylglycosaminuria
Aspergillosis
Asphyxia neonatorum
Asthenia
Asthenia
Asthenophobia
Asthma
Astrocytoma
Ataxia telangiectasia
Atelectasis
Atelosteogenesis, type II
Atherosclerosis
Athetosis
Atopic Dermatitis
Atrial septal defect
Atrioventricular septal...
Atrophy
Attention Deficit...
Autoimmune hepatitis
Autoimmune...
Automysophobia
Autonomic dysfunction
Familial Alzheimer disease
Senescence
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

In APL, there is an abnormal accumulation of immature granulocytes called promyelocytes. The disease characterized by a chromosomal translocation involving the retinoic acid receptor alpha (RARα) gene and is unique from other forms of AML in its responsiveness to all trans retinoic acid (ATRA) therapy.

Signs and symptoms

Signs and symptoms of acute promyelocytic leukemia are similar to other forms of AML. The accumultation of promyelocytes in the bone marrow results in a reduction in the production of normal red blood cells and platelets resulting in anemia and thrombocytopenia. Either leukopenia or leukocytosis may be observed in the peripheral blood.

Symptoms include:

  • Fatigue, weakness, shortness of breath (from anemia)
  • Easy bruising and bleeding (from thrombocytopenia and coagulopathy)
  • Fever and infection (from lack of normal white blood cells)

In addition, acute promyelocytic leukemia is frequently associated with bleeding caused by disseminated intravascular coagulopathy.

Epidemiology

Acute promyelocytic leukemia represents 5-8% of AML in adults. The median age is approximately 40 years, which is considerably younger than the other subtypes of AML (70 years). The incidence is increased in Latin American countries.

Pathogenesis

Acute promyelocytic leukemia is characterized by a chromosomal translocation involving the retinoic acid receptor-alpha gene on chromosome 17. In 95% of cases of APL, retinoic acid receptor-alpha (RARα) gene on chromosome 17 to the promyelocytic leukemia gene (PML) on chromosome 15.

Four other gene rearrangements have been described in APL fusing RAR to promyelocytic leukemia zinc finger (PLZF), nucleophosmin (NPM), nuclear matrix associated (NuMA), or signal transducer and activator of transcription (STAT) 5b genes.

These fusion proteins disrupt the function of RARα which blocks the normal maturation of granulocytes. Although the chromosomal translocation involving RARa is believed to be the initiating event, additional mutations are required for the development of leukemia.

Diagnosis

Acute promyelocytic leukemia can be distinguished from other types of AML based on morphologic examination of a bone marrow biopsy or aspirate. Definitive diagnosis requires testing for the RARα fusion protein and may be obtained by polymerase chain reaction (PCR), fluorescent in situ hybridization (FISH), or conventional cytogenetics of peripheral blood or bone marrow.

Treatment

APL is unique among the leukemias distinguished by its sensitivity to all-trans retinoic acid (ATRA), a derivative of vitamin A. Treatment with ATRA causes differentiation of the immature leukemic promyelocytes into mature granulocytes. ATRA is typically combined with anthracycline based chemotherapy resulting in a clinical remission in approximately 90% of patients.

Read more at Wikipedia.org


[List your site here Free!]


Acute Interstitial Pneumonitis Occurring After Consolidation Chemotherapy With High Dose Cytarabine For Acute Myelogenous Leukemia - Abstract
From CHEST, 10/1/99 by Poh Hock Leng

Introduction: Acute interstitial pneumonitis is an uncommon complication of cytarabine. We report a case of acute interstitial pneumonitis caused by cytarabine with good response to steroid therapy.

Case Presentation: A 50 year old woman was admitted for neutropenic fever 2 weeks after receiving high dose cytarabine at 5.6 grams (3 g/m. sq.) every 12 hours for 3 days for her second consolidation chemotherapy for acute myelogenous leukemia (AML). She had fever and a dry nonproductive cough on admission. She was diagnosed with AML in Dec 1998 and had induction chemotherapy with 95 mg. of daunorubicin and 200 mg. of cytarabine every 24 hours for 3 days. The first consolidation chemotherapy was in Feb. 1999 with high dose cytarabine at 5.6 grams (3 g/m. sq.) every 12 hours for 3 days. On exam, her temperature was 103 [degrees] F, blood pressure 128/84, pulse rate 86/min, respiratory rate 14/min and oxygen saturation was 94% on room air. The lungs were clear to auscultation. Chest X ray was clear. The white blood cell count (WBC) was 300 cells/uL. She was given levofloxacin and gentamicin for empiric antibiotic coverage, blood and platelet transfusions. Four days after admission the WBC rose to 7400 cells/uL., with 58% neutrophils, 6% lymphocytes, 33% monocytes and 1% eosinophils. Her dyspnea and cough worsened and oxygen saturation dropped to 86% on room air. A repeat CXR showed new interstitial infiltrates. A high resolution CAT scan of the chest showed diffuse ground glass infiltrates in both lung fields. Bacterial cultures from the bronchoalveolar lavage were unremarkable. Pneumocystis carinii, fungi, Legionella and acid fast bacilli were not detected in the bronchoalveolar lavage. Fungal and viral cultures were negative. A transbronchial lung biopsy showed intense inflammatory interstitial cellular infiltrates and the presence of reactive type 2 pneumocytes, indicative of a drug-induced reaction. In some areas, the inflammatory cellular reaction extended into the alveolar space. She was started on 3 mg/kg/day of methylprednisolone for drug-induced acute interstitial pneumonitis. Within 72 hours her symptoms improved remarkably and she was weaned off the oxygen. The steroids were tapered over 4 weeks. A repeat CT chest showed resolution of the ground glass infiltrates.

Discussion: The observations in this case suggest that high dose cytarabine can lead to a drug-induced acute interstitial pneumonitis, in the absence of infection and use of other chemotherapeutic agents. This is in contrast to noncardiogenic pulmonary edema, which is a known complication of cytarabine as reported in several studies. The histology seen in this patient differs from previous reports in that there is primarily a cellular inflammatory interstitial process, with extension of the inflammation into the alveoli in some areas. Additionally, a dramatic response to steroids and the fact that her symptoms worsened as her WBC count began to rise imply an immunologic lung injury. It is speculative whether this process is a harbinger of further lung injury that may eventually manifest as noncardiogenic pulmonary edema.

Conclusion: Acute interstitial pneumonitis can occur as a complication of cytarabine and this condition is highly responsive to steroid therapy.

References

[1] Haupt et al. Noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia. The American Journal of Medicine 1981; 70:256-261

[2] Andersson et al. Fatal pulmonary failure complicating high dose cytosine arabinoside therapy in acute leukemia. Cancer 1990; 65:1079-1084

[3] Jehn et al. Noncardiogenic pulmonary edema complicating intermediate and high dose Ara-C for relapsed acute leukemia. Medical Oncology and Tumour Pharmacology 1988; Vol 5. 1.41-47

[4] Motomura et al. Interstitial pneumonia induced by combination therapy with low dose cytarabine and granulocyte colony-stimulating factor. American Journal of Hematology (letter) 1995; 49(4):364

Poh Hock Leng, MD, B. Murillo, MD, A. Fraire, MD--University of Massachusetts, Worcester, Massachusetts, USA

COPYRIGHT 1999 American College of Chest Physicians
COPYRIGHT 2000 Gale Group

Return to Acute promyelocytic leukemia
Home Contact Resources Exchange Links ebay